Anti-ErbB2 Affibody® Molecule (FITC) (ab31891)

ab31891 を使用した論文を発表された方は、こちらまでお知らせください。データシートに掲載させていただきます。

ab31891 は 3 報の論文で使用されています。

  • Globerson-Levin A  et al. Elimination of progressive mammary cancer by repeated administrations of chimeric antigen receptor-modified T cells. Mol Ther 22:1029-38 (2014). PubMed: 24572294
  • Hurrell T & Outhoff K Human epidermal growth factor receptor 2-positive breast cancer: which cytotoxic agent best complements trastuzumab's efficacy in vitro? Onco Targets Ther 6:693-701 (2013). Flow Cyt ; Human . PubMed: 23814468
  • Zhao Y  et al. A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J Immunol 183:5563-74 (2009). Flow Cyt ; Human . PubMed: 19843940

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"